Crystina C. Bronk

PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice

When used as therapy for hematopoietic malignancies, allogeneic BM transplantation (BMT) relies on the graft-versus-leukemia (GVL) effect to eradicate residual tumor cells through immunologic mechanisms. However, graft-versus-host disease (GVHD), which is initiated by alloreactive donor T cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to hematopoietic and epithelial tissues, is a potentially lethal complication of allogeneic BMT. To enhance the therapeutic potential of BMT, we sought to find therapeutic targets that could inhibit GVHD while preserving GVL and immune responses to infectious agents. We show here that T cell responses triggered in mice by either Listeria monocytogenes or administration of antigen and adjuvant were relatively well preserved in the absence of PKC isoform theta (PKCtheta), a key regulator of TCR signaling. In contrast, PKCtheta was required for alloreactivity and GVHD induction. Furthermore, absence of PKCtheta raised the threshold for T cell activation, which selectively affected alloresponses. Most importantly, PKCtheta-deficient T cells retained the ability to respond to virus infection and to induce GVL effect after BMT. These findings suggest PKCtheta is a potentially unique therapeutic target required for GVHD induction but not for GVL or protective responses to infectious agents.

Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells

TANK-binding kinase 1 (TBK1) has emerged as a novel therapeutic target for unspecified subset of lung cancers. TBK1 reportedly mediates prosurvival signaling by activating NF-κB and AKT. However, we observed that TBK1 knockdown also decreased viability of cells expressing constitutively active NF-κB and interferon regulatory factor 3. Basal phospho-AKT level was not reduced after TBK1 knockdown in TBK1-sensitive lung cancer cells, implicating that TBK1 mediates unknown survival mechanisms. To gain better insight into TBK1 survival signaling, we searched for altered phosphoproteins using mass spectrometry following RNAi-mediated TBK1 knockdown. In total, we identified 2,080 phosphoproteins (4,621 peptides), of which 385 proteins (477 peptides) were affected after TBK1 knockdown. A view of the altered network identified a central role of Polo-like kinase 1 (PLK1) and known PLK1 targets. We found that TBK1 directly phosphorylated PLK1 in vitro. TBK1 phosphorylation was induced at mitosis, and loss of TBK1 impaired mitotic phosphorylation of PLK1 in TBK1-sensitive lung cancer cells. Furthermore, lung cancer cell sensitivity to TBK1 was highly correlated with sensitivity to pharmacological PLK inhibition. We additionally found that TBK1 knockdown decreased metadherin phosphorylation at Ser-568. Metadherin was associated with poor outcome in lung cancer, and loss of metadherin caused growth inhibition and apoptosis in TBK1-sensitive lung cancer cells. These results collectively revealed TBK1 as a mitosis regulator through activation of PLK1 and also suggested metadherin as a putative TBK1 downstream effector involved in lung cancer cell survival.

Lung tumor NF-κB signaling promotes T cell–mediated immune surveillance

NF-κB is constitutively activated in many cancer types and is a potential key mediator of tumor-associated inflammation, tumor growth, and metastasis. We investigated the role of cancer cell NF-κB activity in T cell-mediated antitumor responses. In tumors rendered immunogenic by model antigen expression or following administration of antitumor vaccines, we found that high NF-κB activity leads to tumor rejection and/or growth suppression in mice. Using a global RNA expression microarray, we demonstrated that NF-κB enhanced expression of several T cell chemokines, including Ccl2, and decreased CCL2 expression was associated with enhanced tumor growth in a mouse lung cancer model. To investigate NF-κB function in human lung tumors, we identified a gene expression signature in human lung adenocarcinoma cell lines that was associated with NF-κB activity level. In patient tumor samples, overall lung tumor NF-κB activity was strongly associated with T cell infiltration but not with cancer cell proliferation. These results therefore indicate that NF-κB activity mediates immune surveillance and promotes antitumor T cell responses in both murine and human lung cancer.

Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice

Allogeneic hematopoietic cell transplantation (HCT) is the most effective therapy for hematopoietic malignancies through T-cell-mediated graft-vs-leukemia (GVL) effects but often leads to severe graft-vs-host disease (GVHD). Given that protein kinase Cθ (PKCθ), in cooperation with PKCα, is essential for T-cell signaling and function, we have evaluated PKCθ and PKCα as potential therapeutic targets in allogeneic HCT using genetic and pharmacologic approaches. We found that the ability of PKCα(-/-)/θ(-/-) donor T cells to induce GVHD was further reduced compared with PKCθ(-/-) T cells in relation with the relevance of both isoforms to allogeneic donor T-cell proliferation, cytokine production, and migration to GVHD target organs. Treatment with a specific inhibitor for both PKCθ and PKCα impaired donor T-cell proliferation, migration, and chemokine/cytokine production and significantly decreased GVHD in myeloablative preclinical murine models of allogeneic HCT. Moreover, pharmacologic inhibition of PKCθ and PKCα spared T-cell cytotoxic function and GVL effects. Our findings indicate that PKCα and θ contribute to T-cell activation with overlapping functions essential for GVHD induction while less critical to the GVL effect. Thus, targeting PKCα and PKCθ signaling with pharmacologic inhibitors presents a therapeutic option for GVHD prevention while largely preserving the GVL activity in patients receiving HCT.

NF‐κB is crucial in proximal T‐cell signaling for calcium influx and NFAT activation

In the accepted model of T‐cell activation, parallel signal‐transduction pathways activate the transcription factors NF‐κB, NFAT, and AP‐1 to drive clonal expansion of T cells in response to Ag. Genome‐wide transcriptional profiling following Ag‐induced CD8+ T‐cell activation in C57BL/6 mouse T cells revealed that genes regulated by NFAT were also reduced in the absence of NF‐κB p50 and cRel subunits. Importantly, p50−/−cRel−/−CD8+ T cells had significantly diminished NFAT and AP‐1 activation compared with WT or PKCθ−/− CD8+ T cells. Attenuated NFAT activation after TCR engagement was associated with reduced calcium influx, PLCγ and Zap70 activation. Interestingly, pharmacological bypass of PLCγ‐regulated pathways largely rescued p50−/−cRel−/− T‐cell proliferative defects. These results indicate a crucial and unexpected requirement for NF‐κB p50 and cRel subunits in proximal TCR signaling and calcium responses. They further suggest that key defects in T cells in the absence of NF‐κB pathway components may be due to impaired proximal T‐cell signaling.

Targeting PKCθ in alloreactivity and graft-versus- host-disease: unanswered questions and therapeutic potential

Protein kinase C isoform θ (PKCθ) is a key modulator of TCR signaling and mediates activation of NF-κB, NF-AT, and AP-1 transcription factors. Although in vitro studies of PKCθ-/- T cells have shown impaired activation responses, in vivo studies indicate that PKCθ requirement is not universal. While PKCθ is important in induction of experimentally induced autoimmune diseases in mice and generation of Th2 responses, it is not essential for induction of T cell proliferative and cytotoxic responses against influenza virus, LCMV, and vaccinia virus. The context-specific involvement of PKCθ in T cell responses suggests that inhibition of PKCθ may be beneficial in some but not all situations. In the bone marrow transplantation (BMT) setting, we have shown that graft-versus-host-disease (GVHD) cannot be induced in the absence of PKCθ. However, graft-versus-leukemia effects and T cell ability to clear virus infection remains intact. Therefore, PKCθ is a potential therapeutic target in BMT, inhibition of which may prevent GVHD while retaining anti-tumor and anti-infection responses.

Abstract 937: Dissection of KRAS-driven survival signaling networks via phosphoproteomics in lung cancer cells.

KRAS mutation accounts for development of approximately 30% of lung adenocarcinoma yet therapeutic options remain limited. We report our efforts to explore downstream signaling proteins driven by KRAS, including TANK-binding kinase 1 (TBK1), through a mass spectrometry based phosphoproteomics approach. We hypothesized that such a search would identify key survival proteins as well as uncover potential adaptive resistance mechanisms. We identified proteins whose phosphorylation is regulated TBK1 using SILAC and mass spectrometry following RNAi-mediated TBK1 knockdown. A cohesive network view of the underlying results centered major effects on Polo-like Kinase 1 (PLK1) and decreased phosphorylation of its targets implicating TBK1 as involved in mitosis. TBK1 activity was induced especially in late G1 and M phase, and loss of TBK1 sensitized lung cancer cells to a mitotic stressor. Surprisingly, we found that TBK1 knockdown increased phosphorylation of oncogenic kinases, including EGFR, Met, and ERK1/2. We screened multiple tyrosine kinase inhibitors in combination with TBK1 loss and found the pro-apoptotic effect of TBK1 loss was enhanced by dasatinib, a Src-family kinase inhibitor, providing a mechanistic basis for rational combinatorial therapies involving TBK1. Moving upstream, we analyzed global phosphoproteome change after KRAS knockdown and identified unexpected role of KRAS involved in CDK1 regulation as well as potential adaptive resistant mechanisms that can protect cells against KRAS loss. Finally, we have started exploring changes in the programmed kinome in KRAS mutated lung cancer cells following exposure to MEK inhibitors using activity based protein profiling. Initial experiments have characterized phenotypic effects of two MEK inhibitors in a subset of KRAS mutated lung cancer cells and preliminary studies have identified increased levels of some kinases following MEK inhibition. Collectively, we expect this kinome and phosphoproteomic network based approach will provide better insights into survival signaling mechanism maintaining survival of KRAS mutant lung cancer cell as well as novel therapeutic strategies for this cancer subtype. Updated work will be presented. Supported by the SPORE in Lung Cancer (P50-CA119997) Citation Format: Jae-Young Kim, Eric A. Welsh, Bin Fang, Umut Oguz, Jiannong Li, Fumi Kinose, Crystina Bronk, Amer A. Beg, Ann Chen, Steven Eschrich, John Koomen, Eric B. Haura. Dissection of KRAS-driven survival signaling networks via phosphoproteomics in lung cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 937. doi:10.1158/1538-7445.AM2013-937

IKKβ-induced inflammation impacts the kinetics but not the magnitude of the immune response to a viral vector

Microbial adjuvants in vaccines activate key transcription factors, including NF‐κB and interferon response factors (IRFs). However, the individual role of these transcription factor pathways in promoting adaptive immunity by adjuvants is not clear. It is widely believed that induction of a strong inflammatory response potentiates an adaptive immune response. In this study, we sought to determine whether activation of the pro‐inflammatory inhibitor of κB kinase β (IKKβ) canonical NF‐κB pathway promoted vaccine‐induced immune responses. An adenovirus expressing constitutively activated IKKβ (AdIKK) induced robust DC maturation and high expression of key cytokines compared with a control virus. In vivo, AdIKK triggered rapid inflammation after pulmonary infection, increased leukocyte entry into draining LNs, and enhanced early antibody and T‐cell responses. Notably, AdIKK did not influence the overall magnitude of the adaptive immune response. These results indicate that induction of inflammation by IKKβ/NF‐κB in this setting impacts the kinetics but not the magnitude of adaptive immune responses. These findings therefore help define the individual role of a key pathway induced by vaccine adjuvants in promoting adaptive immunity.